Notification No. 83/2017-Customs Dated 31/10/2017

Seeks to amend notification No. 16/2017-Customs dated the 20th April, 2017.-

G.S.R. (E). -In exercise of the powers conferred by sub-section (1) of section 25 of the Customs Act, 1962 (52 of 1962), the Central Government, on being satisfied that it is necessary in the public interest so to do, hereby makes the following further amendments in the notification of the Government of India, in the Ministry of Finance (Department of Revenue), No. 16/2017-Customs, dated the 20th April, 2017, published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i),vide number G.S.R.394 (E), dated the 20thApril, 2017, namely:-

In the said notification, in the Table, after serial number 27 and the entries relating thereto, the following serial numbers and entries shall be added, namely:-

 

(1) (2) (3) (4)
"28
Erlotinib (Tarceva)
The Blue Tree
Roche Products (India) Private Limited
29
Trastuzumab (Herclon)
The Blue Tree Roche Products (India) Private Limited
30 Pertuzumab (Perjeta) The Blue Tree Roche Products (India) Private Limited
31
Transtuzumab Emtansine (Kadcyla)
The Blue Tree Roche Products (India) Private Limited
32
Obinutuzumab (Gazyva)
The Blue Tree Roche Products (India) Private Limited
33
Bevacizumab (Avastin)
The Blue Tree Roche Products (India) Private Limited
34
Tocilizumab (Actemra)
Care for Joints Roche Products (India) Private Limited
35
Mycophenolate Mofetil (CellCept)
Aarambh Roche Products (India) Private Limited
36
Avonex (Interferon Beta 1A)
Reach UCB India Private Limited
37
Tysabri (Monoclonal Antibody)
Reach UCB India Private Limited
38
Tecfidera (Di-methyl Fumarate)
Reach UCB India Private Limited
39 Plegridy (Peggylated Interferon Beta 1A) Reach UCB India Private Limited
40
Sorafenib (Nexavar)
NexCSP (Nexavar Cancer Survivorship Program)
Bayer Zydus Pharma Private Limited
41
Sirturo (Bedaquiline)
Bedaquiline Compassionate Use Program
Janssen India, Johnson & Johnson Private Limited
42
Darzalex (Daratumumab)
Daratumumab Patient Assistance Program
Janssen India, Johnson & Johnson Private Limited
43 SUTENT
-Patients initially pay for 12 strips (value equivalent of 50 mg) and gets assistance of 12 strips free.
-Post purchase of 12 strips patients receive the drug free until prescribed by treating physicians.-Full subsidy for BPL patients
Pfizer Products India Private Limited
44 CRIZALK
Patients will pay for 8 bottles (either 200 mg or 250 mg) and post that will get the drug free until prescribed by treating physician.-Full subsidy for BPL patients
Pfizer Products India Private Limited
45 INLYTA
Sutent Patients who progresses and prescribed lnlyta as 2nd line pays for 1 strip and gets 1 strip free.-Patients who progresses on other 1st line TKI pays for 2 strips and get 1 strip free.-Ful1subsidy for BPL patients
Pfizer Products India Private Limited
46 PALBACE
Patients will pay for 10 cycles and post that will get free drug support until  prescribed by treating physicians.-Full subsidy for BPL patients
Pfizer Products India Private Limited
47 ENBREL
ENLIVEN-Enbrel 50 mg: 4+2PAP. Any further repeat purchase will be given at a further discounted price
Pfizer Limited

[F. No. 332/24/2010-TRU (Pt. I)]

(Ruchi Bisht)
Under Secretary to the Government of India

Note: The principal notification No. 16/2017-Customs, dated the 20th April, 2017, published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i) vide number G.S.R.394 (E), dated the 20th April, 2017.